Valuation
- Market cap
- 280,586,000
- Revenue TTM
- $35,110,000
- Net income TTM
- $-79,200,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -225.58%
- Debt to equity
- 0.49
Trading
- Volume
- 911,400
- Avg volume
- 902,820
- Day's range
- $2.74 – $2.86
- Shares out
- 99,147,000
- Stochastic %K
- 10%
- Beta
- 0.46
- Analysts
- Strong Sell
- Price target
- $11.60
Company profile
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis s...
Show more
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 857 529 8300
- Website
- https://www.x4pharma.com
- Address
- 61 North Beacon Street, 4th Floor, Boston, United States
Latest news
No headlines yet.
